New NIAID Radiation and Nuclear Countermeasures Program’s DAIT Council-Approved Research Concepts (January 27, 2014)
BAA-13-100-SOL-00013: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures for BARDA. Posted July 31, 2013
BAA-13-100-SOL-00014: Science and Technology Platforms Applied to Medical Countermeasure Development (Innovations) for BARDA. Posted July 31, 2013
Request for Information (Department of the Army – Solicitation #W911QY-13-S-0003): Identification of Radiological Diagnostic Devices. Due Date: March 26, 2013.
DARPA-SN-13-24: Reducing Ionizing Radiation Risk (RFI). Receipt date April 2, 2013.
Request for Information: Joint Program Executive Office for Chemical and Biological Defense (CBMS-MITS), Department of Defense: Identification of a Physical Dosimetry or Biodosimeter as a Medical Radiation Countermeasure (MRADC) (responses due Jan. 28, 2012).
Mechanisms, Detection and Countermeasure Research and Development for Mixed-Field Radiation Exposure (responses due February 3, 2012)
NOT-AI-11-044 - Request for Information (RFI): Pediatric and Geriatric Animal Models and Medical Countermeasures Development for Mitigation and Treatment of Radiation Exposure from a Radiological or Nuclear Incident (response date July 19, 2011)
RFI-BARDA-08-21A: Physical and Biological Dosimetry Techniques and Devices Useful in Initial Triage After Radiologic and Nuclear Events. Issued by ASPR, OS, DHHS on May 20, 2008.
NOT-AI-07-033: Agents to Enhance Platelet Regeneration and Increase Survival following Radiation Exposure (Issued May 24, 2007).
NOT-AI-07-028: GLP Radionuclide Testing Facilities (Issued March 23, 2007).
Centers for Medical Countermeasures Against Radiation—Request for Information (Released April 9, 2004).
Neutropenia RFI Issued by HHS (Released October 29, 2004).
RFA-AI-12-023: Development of Medical Countermeasures for Post-Exposure Mitigation/Treatment of Injuries Resulting from a Radiation/Nuclear Incident (U01)
RFA-AI-11-033: Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Injuries (R01)
RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)
RFA-DK-08-010: Intestinal Stem Cell Consortium (U01) - Co-Funded by the NIAID Radiation/Nuclear Program. Receipt date: March 18, 2009.
NSBRI-RFA-08-02: Research Opportunities Soliciting an NSBRI Center of Acute Radiation Research for Ground-Based Studies on Acute Radiation Effects (Due date: May 8, 2008).
RFA-AI-07-040, BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Pulmonary Injury: Project Bioshield (RC1) (Due date: March 11, 2008).
RFA-AI-07-037: BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Cutaneous Injury: Project Bioshield (RC1) (Due date: March 11, 2008).
RFA-AI-07-038: Radiation Combined Injury: Radiation Exposure in Combination with Burn, Wound, Trauma, or Infection (Phased Innovation Award [R21/R33]) (Due date: January 24, 2008
RFA-AI-07-039: Mechanisms, Diagnosis, and Treatment of Radiation Injury from a Nuclear Accident or Terrorist Attack (R01) (Due date: January 15, 2008).
RFA-AI-07-036: Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) (Due date: January 9, 2008).
RFA-AI-07-013: Medical Countermeasures to Restore Gastrointestinal Function after Radiation Exposure: Project Bioshield (RC1) (Due date: April 19, 2007).
NASA Research Announcement (NRA) for Ground-Based Studies in Radiation Biology Solicitation No. NNJ07ZSA001N—External link (Issued January 5, 2007).
Announcement: Biodefense Countermeasure Development: Project Bioshield: Protecting the Immune System Against Radiation (Released July 23, 2004).
Centers for Medical Countermeasures against Radiation—RFA-AI-04-045 (Released November 23, 2004).
Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01)—RFA-AI-06-030 (Released March 30, 2006).
PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])
CMCR Public Briefing (December 15, 2004).
BAA-NIAID-DAIT-NIHAI2013166 - Development of Medical Countermeasures to Enhance Platelet Regeneration and Survival Following Radiation Exposure from a Radiological/Nuclear Incident. Due Date July 1, 2013
FDA BAA-12-00118: Food and Drug Administration Broad Agency Announcement for the Advanced Research and Development of Regulatory Science and Innovation. Continuously open announcement valid through May 22, 2013.
BARDA-CBRN-BAA-12-100-SOL-00011: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medicine Countermeasures
Department of Defense: CHEMICAL AND BIOLOGICAL DEFENSE PROGRAM SBIR 13.1 Proposal Submission – Topic CBD13-108: Rapid biodosimetry for accurate assessment of individual radiation exposure levels (Due Date – January 16, 2013).
BARDA-BAA-11-100-SOL-009: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures)
PHS 2011-1: Solicitation of NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals. Research topics identified include: NCI Topic 291 - Radioprotector/Mitigator Development to Decrease Normal Tissue Injury During Radiotherapy. Due Date: November 8, 2010. Download Solicitation Package (PDF).
RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services
BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies
BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency
Issued by the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (BAA-BARDA-09-36): Point of Care of High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events.
Issued by the Defense Threat Reduction Agency (DTRA): BAA for Chemical and Biological Technologies Directorate New Initiatives FY2010-FY2011, October 17, 2008. See BAA Amendment 1, October 30, 2008 for Radiation Topics.
Issued by the U.S. Special Operations Command, June 26, 2007: Broad Agency Announcement, Bio-Medical Research Topics.
Defense Threat Reduction Agency’s (DTRA's) Basic Research Program for Combating Weapons of Mass Destruction (WMD) and Basic Research in the Chemical Biological Defense Program. (HDTRA1-07-BRCWMD-BAA. Phase I proposal receipt deadline: June 8, 2007.)
RFP Issued by the U.S. Army Space and Missile Defense Command: Solicitation # W9113M-07-R-0002: To Develop and Deliver in Minimal Time and Minimal Cost, an FDA-Approved Medical Countermeasure for Radiation Injury to Increase Survival following Radiation Exposure (Issued February 16, 2007).
RFP-NIH-NIAID-DAIT-05-46, Development of Improved DTPA for Radionuclide Chelation (Released May 6, 2005).
Draft RFP Issued by the Office of Public Health Emergency Preparedness (HHS): Medical Countermeasures to Mitigate or Treat Neutropenia Associated with Acute Radiation Syndrome (ARS) That Will Support a Public Health Emergency Response to a Radiological or Nuclear Event (RFI-ORDC-05-01A).
Issued April 10, 2007, by the Defense Advanced Research Projects Agency (DARPA): BAA 07-29: Radiation Biodosimetry (RaBid) Announcement.
Issued by the Department of Health and Human Services, May 30, 2007: Therapeutics Applicable for the Treatment of Neutropenia Resulting from Exposure to Ionizing Radiation
Issued by the Department of Defense, CBMS-MITS (Solicitation # W9113M-09-R-0010): Advanced Development of a Medical Radiation Countermeasure (MRC) to treat the Gastrointestinal Subsyndrome of Acute Radiation Syndrome (ARS)
BAA-NIAID-DAIT-NIHAI2012147: Development of Medical Countermeasures to Mitigate or Treat the Gastrointestinal Acute Radiation Syndrome after a Nuclear or Radiation Incident (responses due November 15, 2012)
back to top
Last Updated July 24, 2013
Last Reviewed June 19, 2012